Prescribing trends and safety of clozapine in an older persons mental health population

• Published in: International psychogeriatrics Vol. 31; no. 12; pp. 1823 - 1829
• Main Authors: Law, Alice, Croucher, Matthew
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2019; Cambridge University Press
• Subjects: Adults; adverse effects; Age; Aged; Aged, 80 and over; agranulocytosis; antipsychotic; Antipsychotic Agents - adverse effects; Antipsychotic Agents - therapeutic use; Antipsychotics; Bipolar disorder; Clozapine; Clozapine - adverse effects; Clozapine - therapeutic use; Dementia; Drug dosages; Drug Prescriptions; Drug Resistance; elderly; Female; Geriatrics; Health services; Humans; Male; Medical records; medication; Mental health; Middle Aged; Neutropenia; Neutropenia - chemically induced; New Zealand; Older people; Patients; Population; Practice Guidelines as Topic; Practice Patterns, Physicians' - statistics & numerical data; Psychosis; Psychotic Disorders - drug therapy; Psychotropic drugs; Retrospective Studies; Schizophrenia; Trends; New Zealand; agranulocytosis; elderly; adverse effects; medication; antipsychotic; Clozapine; psychosis
• ISSN: 1041-6102; 1741-203X; 1741-203X
• DOI: 10.1017/S1041610219000255

ABSTRACTObjectivesTo provide additional data concerning the safety, effectiveness and local prescribing trends of clozapine in elderly patients. DesignRetrospective observational case-series analysis. SettingData were collected from the medical files of 167 patients prescribed clozapine. ParticipantsAll patients prescribed clozapine in the last 15 years by the psychogeriatric service in Christchurch, New Zealand. The subjects were mostly aged over 65; however, patients under 65 are also accepted into the service on a case by case basis if they have an age-related health condition. ResultsTwenty-five (15.0%) patients had their clozapine stopped due to a significant adverse reaction, including eleven who developed significant neutropenia. Seventy-four (44.3%) of the patients had no recorded side effects at all. Sixty-five (38.9%) of our elderly patients died while taking clozapine, though none of these deaths was felt to be related to clozapine use. Several patients safely initiated clozapine in either their own home or a nursing home without requiring hospital admission. Only two patients ceased clozapine due to ineffectiveness, and one hundred, forty-two (86.1%) of the patients had positive comments in their medical record regarding the benefits of clozapine for their particular case. ConclusionsWe found clozapine could be used safely and effectively in our patient group, for a wider range of indications and at lower doses than younger patients. Data collection regarding cause of death in elderly patients who were ever prescribed clozapine was problematic, and more research into this area is required.